Online Cognitive Behavioral Therapy- Enhanced for Binge Eating Disorder

Recruiting

• Conditions: Binge eating disorder; Eating disorder; 10014067

• Registration Number: NL-OMON48265
• Lead Sponsor: Arkin (Amsterdam)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 180

Inclusion Criteria

1. Binge Eating Disorder or Other Specified Eating Disorder (OSFED), most
similar to Binge Eating disorder diagnosis
2. Age >= 18
3. 19.5 <= BMI < 40
4. Moderately proficient in Dutch
5. Willing to provide contact details including (mobile)phone number
6. Referral letter from their general practitioner (GP)
7. Internet access
8. Computer/tablet at home and willingness to use this for treatment and
research purposes
9. Ability to buy *Overcoming binge eating* written by Christopher Fairburn. In
case the participant is not able to buy the book, Novarum will provide an
exemplar during treatment.
10. Informed consent regarding the study provided by the patient
11. Medication that might influence eating behavior such as, Lithium,
Mitrazepine and anti- psychotic stimulants

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in this study:
1. Acute psychosis
2. Acute depression
3. Suicidal ideation
4. Self induced vomiting as compensatory behavior
5. Receivement of treatment for ED during the past months
6. Pregnancy
7. Expected absence during treatment period
8. Bariatric surgery

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is to compare the efficacy of GSH CBT-E on the amount<br /><br>of binge free days pre- and post-treatment. Primary parameter will be measured<br /><br>through the Eating Disorder Examination (EDE) and Eating Disorder Examination<br /><br>Questionnaire (EDE-Q). All questionnaires will be assessed at start and end of<br /><br>treatment. In week 5, 24 and 36 the EDE-Q will also be conducted. </p><br>